Metformin to Prevent the Metabolic Complications of Olanzapine.

Trial Profile

Metformin to Prevent the Metabolic Complications of Olanzapine.

Completed
Phase of Trial: Phase IV

Latest Information Update: 11 Dec 2012

At a glance

  • Drugs Metformin (Primary) ; Olanzapine
  • Indications Metabolic syndrome
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 17 Aug 2012 Actual end date (1 Aug 2011) added as reported by ClinicalTrials.gov.
    • 01 Aug 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 16 Sep 2010 Planned end date changed from 1 Aug 2010 to 1 Aug 2011 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top